Consellería de Sanidade

2016

1. Corrigendum to "Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance". [Rep. Pract. Oncol. Radiother. 20 (2015) 259-272]

   Reports of Practical Oncology and Radiotherapy

2. Evidence-based recommendations of postoperative radiotherapy in lung cancer from Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

   Clinical and Translational Oncology, Vol. 18, Núm. 4, pp. 331-341

3. GRAY-B: An open label multicenter phase-2 GEM study on ipilimumab and radiation in patients with melanoma and brain metastases

   Annals of Oncology, Vol. 27, pp. vi383

4. Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients

   Radiotherapy and Oncology, Vol. 121, Núm. 3, pp. 431-439

5. Management of prostate cancer patients following radiation therapy after radical surgery referred from urology to radiation oncology departments in Spain

   Clinical and Translational Oncology, Vol. 18, Núm. 9, pp. 884-892

6. Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer

   EBioMedicine, Vol. 10, pp. 150-163

7. No role for trimodality therapy and consolidation chemotherapy compared with concurrent radiochemotherapy alone in stage III non-small-cell lung cancer

   Journal of Clinical Oncology

8. Surgery for Stage IIIA Non-Small-cell Lung Cancer: Lack of Predictive and Prognostic Factors Identifying Any Subgroup of Patients Benefiting from It

   Clinical Lung Cancer, Vol. 17, Núm. 2, pp. 107-112

9. The number of risk factors is the strongest predictor of prostate cancer mortality: multi-institutional outcomes of an extreme-risk prostate cancer cohort

   Clinical and Translational Oncology, Vol. 18, Núm. 10, pp. 1026-1033